REGENXBIO Inc. (RGNX) Financials

RGNX Assets vs Liabilities

DateAssetsLiabilities
2023-12-31 574.0 million 262.2 million
2023-09-30 633.8 million 270.7 million
2023-06-30 682.5 million 276.6 million
2023-03-31 747.8 million 282.7 million

RGNX Free Cash Flow and Stock based compensation

Graph available only for supporters. Become a supporter to see it.
DateFree Cash FlowStock based compensation
2023-12-31 -41.9 million 8.3 million
2023-09-30 -50.8 million 10.2 million
2023-06-30 -49.9 million 10.5 million
2023-03-31 -85.7 million 11.2 million

RGNX Net Income

No data available :(

RGNX Cash and Debt

Graph available only for supporters. Become a supporter to see it.
DateCashDebtCapital Lease
2023-12-31 275.3 million - 89.3 million
2023-09-30 301.9 million - 90.7 million
2023-06-30 320.1 million - 91.6 million
2023-03-31 331.8 million - 93.3 million

RGNX Shares Outstanding

Graph available only for supporters. Become a supporter to see it.
DateShares Outstanding
2023-12-31 44.0 million
2023-09-30 43.9 million
2023-06-30 43.5 million
2023-03-31 43.5 million

RGNX Expenses

Graph available only for supporters. Become a supporter to see it.
DateCapexR&DG&AS&M
2023-12-31 1.1 million 55.7 million 19.1 million -
2023-09-30 1.4 million 58.2 million 23.1 million -
2023-06-30 2.6 million 59.9 million 23.7 million -
2023-03-31 4.8 million 58.5 million 22.6 million -

RGNX Cost of Revenue

Graph available only for supporters. Become a supporter to see it.
DateRevenueCost of Revenue
2023-12-31 22.2 million 11.2 million
2023-09-30 28.9 million 12.4 million
2023-06-30 20.0 million 9.5 million
2023-03-31 19.1 million 4.1 million

RGNX

Price: $16.19

52 week price:
11.83
28.80

Earnings Per Share: -6.02 USD

P/E Ratio: -2.43

Exchange: NMS

Sector: Healthcare

Industry: Biotechnology

Volume: 295200

Ebitda: -20.6 million

Market Capitalization: 939.2 million

Links: